Articles By Aurelie Najm, MD, PhD
RA: MACE Events with Opioids vs. NSAIDs
22 November 2022
Addressing chronic pain often leads general practitioners and specialists to prescribe opioids. However, opioids (weak and strong) have not demonstrated efficacy in long-term pain management; their chronic use could even worsen pain in users. Opioids prescription is often perceived as being safer than NSAIDs prescription, especially in respect to MACE.
Read Article
Infections in pre-RA: a cause or a consequence?
12 November 2022
Rheumatoid arthritis is known to be associated with a higher risk of infections. In abstract 0535, Porter and colleagues have assessed infection rates in the pre-RA and early RA phases as defined by antibiotics prescription and hospital admissions with an infection main diagnostic code in the UK National database.
Read Article
Survival and Mortality in RA: time to move away from “one-size fits all”?
12 November 2022
Patients with RA are known to have a higher mortality risk than the general population.
Read Article
JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?
16 June 2022
Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases.
Read Article
Time to consider gender stratification in AxSpA diagnosis and management
07 June 2022
Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked.
Read Article
Pre-clinical RA: starting off the wrong foot
09 December 2021
Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.
Read Article
TNF inhibitors and radiographic progression in axSpA
03 December 2021
A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.
Read Article
TNF inhibitors and radiographic progression in axSpA
07 November 2021
A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.
Read Article
Pre-clinical RA: starting off the wrong foot
06 November 2021
Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.
Read Article
RA after 70: Too Old for bioDMARDs?
07 June 2021
In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.
Read Article